Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: KEGG:D02003 (
NBT
)
1,323
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
All-trans-retinoic acid (RA) treatment of acute promyelocytic leukemia (APL) cases expressing the t(15;17) product, PML/RARalpha, is a successful example of differentiation therapy. Uncovering RA target genes is of considerable interest in APL. This study comprehensively examines in APL cells transcriptional and post-transcriptional regulation of the novel candidate RA target gene,
G0S2
, the G0/G1 switch gene. Reverse transcription (RT)-polymerase chain reaction (PCR) and heteronuclear PCR assays performed +/- treatment with the protein synthesis inhibitor cycloheximide (CHX) revealed
G0S2
induction within 3 h of RA-treatment. Treatment with the RNA synthesis inhibitor actinomycin D did not implicate
G0S2
transcript stabilization in the RA-mediated increase of
G0S2
mRNA expression. Promoter elements of
G0S2
were cloned into a reporter plasmid and retinoic acid receptor (RAR) co-transfection assays confirmed transcriptional activation after RA-treatment. Consistent with
G0S2
being a direct RA target gene, retinoic acid response element (RARE) half-sites were found in this promoter. Mutation of these sites blocked RA-transcriptional activation of
G0S2
. To extend analyses to the protein expression level, a polyclonal anti-
G0S2
antibody was derived and detected murine and human
G0S2
species. G0S2 protein was rapidly induced in cultured NB4-S1 human APL cells and in APL transgenic mice treated with RA. An RAR pan-antagonist confirmed dependence on RARs for this induction. That these findings are clinically relevant was shown by analyses of APL cells derived directly from patients. These leukemic cells induced both a prominent increase in the cellular differentiation marker nitrotetrazolium blue (
NBT
) staining and marked increase in
G0S2
expression. Taken together, these findings indicate
G0S2
is an RA target gene. The functional role of
G0S2
in retinoid response of APL warrants further study.
...
PMID:G0S2 is an all-trans-retinoic acid target gene. 1863 62